Table 2 Seroprevalence and incidence of CMV infection among healthcare and childcare workers

Overall prevalence

47

29332

53.3 (46.5–60.0)

98 (98–98)

21

3994

4.6 (2.6–7.1)

83 (76–89)

 Childcare workers

24

22194

59.3 (49.8–68.6)

98 (97–98)

9

883

7.4 (3.9–11.8)

89 (81–93)

 Healthcare workers

25

7138

49.5 (40.3–58.7)

97 (97–98)

12

3111

3.1 (1.3–5.6)

48 (0–73)

 Africa

3

95

47.9 (18.5–78.0)

96 (91–98)

-

 North America

26

6781

46.6 (37.9–55.5)

94 (92–95)

15

3272

5.9 (3.3–9.0)

87 (80–91)

 Asia

2

1242

77.9 (49.1–96.8)

91 (68–97)

1

70

2.8 (0.0–8.4)

-

 Europe

15

20924

61.2 (50.2–71.7)

99 (98–99)

3

352

1.1 (0.0–7.4)

15 (0–91)

 Oceania

1

290

52.1 (46.3–57.8)

2

300

2.3 (0.0–10.3)

62 (0–91)

 Anticomplement immunofluorescence

4

1466

60.5 (39.4–79.7)

97 (95–98)

3

1208

2.6 (0.1–7.3)

17 ( 0–91)

 Complement fixation

7

1636

48.6 (31.4–65.9)

98 (97–99)

5

1178

4.4 (1.2–9.2)

72 (29–89)

 ELISA

18

5245

53.1 (42.7–63.3)

98 (95–97)

5

1169

5.0 (1.8–9.5)

93 (88–97)

 Latex agglutination

6

795

47.0 (28.9–65.5)

90 (81–95)

4

258

7.9 (2.8–15.1)

0 (0–85)

 No specify

3

644

24.6 (7.1–48.0)

98 (97–99)

1

42

23.8 (12.0–38.0)

-

 Other

7

19496

66.0 (50.4–80.1)

95 (92–97)

2

125

1.0 (0.0–7.1)

45 (–)

 Restriction endonuclease

2

50

76.0 (41.3–98.8)

42 (–)

1

14

0.0 (0.0–11.9)

-

 Cohort

25

7548

52.1 (42.8–61.3)

97 (97–98)

21

3994

4.6 (2.6–7.1)

83 (76–89)

 Cross-sectional

22

21784

54.7 (44.6–64.6)

98 (97–98)

-

 Good

19

7584

58.9 (48.8–68.7)

98 (97–98)

10

2590

5.8 (2.7–9.8)

88 (79–93)

 Fair

13

3160

51.1 (38.8–63.3)

96 (95–97)

8

1044

3.5 (0.7–7.8)

67 (30–84)

 Poor

15

18588

46.7 (33.7–59.8)

98 (97–98)

3

359

3.9 (0.1–11.4)

92 (80–97)